Chair Julie M. Vose, MD University of Nebraska Medical Center Omaha, Nebraska Faculty John P. Leonard, MD Weill Cornell Medical College New York, New York Lee Lokey, MD prIME Oncology Atlanta, Georgia Susan O'Brien, MD M. D. Anderson Cancer Center Houston, Texas

Owen O'Connor, MD, PhD NYU Langone Medical Center New York, New York Oliver Press, MD, PhD Seattle Cancer Care Alliance Seattle, Washington

Chronic lymphocytic leukemia: Choosing therapy based on prognostic markers
Susan O’Brien, MD

Case #1: Risk-adapted therapy for CLL: Is it ready for "prime time"?
Susan O’Brien, MD

Debate: Conservative or aggressive therapy for mantle cell lymphoma
        Conservative - John P. Leonard, MD
        Aggressive - Julie M. Vose, MD

Follicular lymphoma: What’s new and different?
Oliver Press, MD

Case #2: Follicular lymphoma: Exploring all of the available options
Oliver Press, MD

Novel therapies for non-Hodgkin lymphoma: An update
John P. Leonard, MD

Case #3: Aggressive peripheral T-cell lymphoma: Optimal management
Owen O’Connor, MD, PhD

The growing number of therapeutic options available for patients with subtypes of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma, leaves many important questions currently unanswered, including the appropriate integration of novel agents and the use of prognostic markers to select therapy.  Determining which treatment approach is most appropriate for a given patient requires careful evaluation of individual patient characteristics, physician expertise, and available health-system resources, which require knowledge of current clinical and experimental data in order for the optimal utilization of therapeutic agents and strategies in clinical practice.  Based on the development of new, potentially more effective agents, there exists a need to increase the awareness of practicing physicians regarding the rationale for the development of novel agents, their mechanisms of action, and the proper use of these agents in the management of lymphoma, both alone and in combination with existing therapy modalities, including any important adverse effects that may arise. 

This educational activity is specifically designed for hematologists, oncologists, and other healthcare professionals involved and/or interested in the management of patients with lymphoma.

Upon completion of this educational activity, attendees should better be able to:
    
•    Evaluate the use of prognostic markers to guide the therapeutic decision-making process in patients with chronic lymphocytic leukemia

•    Compare and contrast conservative therapy and aggressive therapy for mantle cell lymphoma, focusing on recent clinical trial data and patient outcomes

•    Discuss available and emerging management options for patients with follicular lymphoma and identify strategies to employ the optimal sequence of therapy

•    Optimize therapeutic planning in patients with aggressive peripheral T-cell lymphoma based on emerging data from clinical trials demonstrating the improved management of this patient population

•    Describe emerging therapies in NHL and evaluate the practical utility of novel agents based on data from clinical studies

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Nebraska Medical Center, Center for Continuing Education; The University of Nebraska Medical Center College of Nursing Continuing Nursing Education; prIME Oncology; Allos Therapeutics, Inc; Cephalon, Inc; Genentech BioOncology; and Millennium, the Takeda Oncology Company do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Nebraska Medical Center, Center for Continuing Education; The University of Nebraska Medical Center College of Nursing Continuing Nursing Education; prIME Oncology; Allos Therapeutics, Inc; Cephalon, Inc; Genentech BioOncology; and Millennium, the Takeda Oncology Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The University of Nebraska Medical Center, Center for Continuing Education, the University or Nebraska Medical Center of Nursing Continuing Nursing Education and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the University of Nebraska Medical Center, Center for Continuing Education and prIME Oncology for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Dr Vose has disclosed that she has received research grant support from Allos Therapeutics, Inc; AnorMed, Inc.; Applied Molecular Evolution, Inc.; Astellas Pharmaceuticals; Bristol-Myers Squibb Company; Celgene Corporation; Genentech BioOncology; Genzyme Corporation; GlaxoSmithKline; Millennium, the Takeda Oncology Company; Novartis Pharmaceutical Corporation; Pharmacyclics; and Rigel. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Leonard has disclosed that he has received consulting fees from Biogen Idec Inc; Biotest; Calistoga Pharmaceuticals; Celgene Corporation; Cell Therapeutics, Inc.; EMD Serono, Inc.; Enzon Pharmaceuticals, Inc.; Genentech BioOncology; GlaxoSmithKline; Gloucester Pharmaceuticals, Inc.; Immunomedics, Inc.; Intellikine; Johnson & Johnson; Millennium, The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lokey has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his discussion.

Dr O’Brien has disclosed that she performs contracted research for Biogen Idec Inc; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech BioOncology; Novartis Pharmaceuticals Corporation; Berlex Laboratories, Inc.; Gemin X; Genta Incorporated; and Hana  BioSciences. She has also received consulting fees from Allos Therapeutics, Inc.; Celgene Corporation; Facet Biotech; Genmab A/S; GlaxoSmithKline; sanofi-aventis; Sunesis Pharmaceuticals, Inc.; and Trubion Pharmaceuticals Inc. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr O’Connor has disclosed that he has received research support from Allos Therapeutics, Inc; Abbott Laboratories; and Eli Lilly and Company. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Press has disclosed that he is the co-founder/consultant to PhaseRx and a consultant to Genentech BioOncology. He is a member of the Speakers’ Bureau to Algeta. Dr Press is also a stock shareholder to Trubion. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The following planners and managers, Brenda C. Ram, CMP (continuing education coordinator), Kathryn Brown Charalambous, PhD (clinical), Trudy Stoddert, ELS (editorial), and Susan Ahn (project planning) hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.